APA (7th ed.) Citation

Adingupu, D. D., Göpel, S. O., Grönros, J., Behrendt, M., Sotak, M., Miliotis, T., . . . Jönsson-Rylander, A. (2019). SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice. Cardiovascular diabetology, 18(1), 16-15. https://doi.org/10.1186/s12933-019-0820-6

Chicago Style (17th ed.) Citation

Adingupu, Damilola D., Sven O. Göpel, Julia Grönros, Margareta Behrendt, Matus Sotak, Tasso Miliotis, Ulrika Dahlqvist, Li-Ming Gan, and Ann-Cathrine Jönsson-Rylander. "SGLT2 Inhibition with Empagliflozin Improves Coronary Microvascular Function and Cardiac Contractility in Prediabetic Ob/ob−/− Mice." Cardiovascular Diabetology 18, no. 1 (2019): 16-15. https://doi.org/10.1186/s12933-019-0820-6.

MLA (9th ed.) Citation

Adingupu, Damilola D., et al. "SGLT2 Inhibition with Empagliflozin Improves Coronary Microvascular Function and Cardiac Contractility in Prediabetic Ob/ob−/− Mice." Cardiovascular Diabetology, vol. 18, no. 1, 2019, pp. 16-15, https://doi.org/10.1186/s12933-019-0820-6.